Aptevo Therapeutics Inc. announces the expansion of its anti-cancer pipeline with the introduction of two new trispecific candidates, APVO452 and APVO451, targeting prostate cancer and multiple solid tumor types.
These candidates leverage the proprietary ADAPTIR-FLEX design to engage tumor antigens, T cells, and immunosuppressive cells simultaneously, ushering in a new era of CD3 therapies.
The development of trispecific molecules represents a significant advancement in addressing the challenges presented by the tumor microenvironment in the treatment of solid tumors.
New Candidates
APVO452 and APVO451 target prostate and multiple solid tumor types, utilizing a novel trispecific design for enhanced efficacy.
Clinical Validation
Lead candidate mipletamig's success in clinical trials supports the introduction of APVO452 and APVO451, demonstrating strong safety and efficacy for the treatment of acute myeloid leukemia.
Trispecific Design
APVO452 and APVO451 are designed to modulate the tumor microenvironment by engaging tumor targeting, T cell activation, and immune costimulation in a single molecule, offering a promising approach to anti-cancer therapy.
- The introduction of trispecific candidates APVO452 and APVO451 signifies Aptevo's commitment to innovation in immuno-oncology, potentially unlocking deeper and more durable anti-tumor responses.
- By simultaneously targeting multiple immune pathways while limiting systemic toxicity, these molecules have the potential to revolutionize the treatment of solid tumors with significant unmet needs.
Aptevo's groundbreaking trispecific molecules herald a new chapter in the fight against cancer, offering a multi-faceted approach to combatting tumor growth and progression. The Company's dedication to developing novel therapies underscores its position as a leader in the field of immuno-oncology.